NCT05128019 (ICIT) is a NA clinical trial of ICIT in Medical Unexplained Physical Symptoms (MUPS), sponsored by University of Oslo.

Who is sponsoring NCT05128019?

NCT05128019 is sponsored by University of Oslo.

What drugs are being tested in NCT05128019?

Interventions in NCT05128019: ICIT.

What condition does NCT05128019 study?

NCT05128019 studies Medical Unexplained Physical Symptoms (MUPS), Subjective Health Complaint.

Is NCT05128019 still recruiting?

NCT05128019 is currently completed. Last updated 17 May 2023.

Last reviewed 2023-05-17 · How we verify

NCT05128019: ICIT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of the Individual Challenge Inventory Tool (ICIT) by General Practitioners

Completed NA Last updated 17 May 2023

What this trial tests

NA trial testing ICIT in Medical Unexplained Physical Symptoms (MUPS) in 459 participants. Completed in 28 February 2023.

Timeline

7 March 2022

Primary endpoint
21 May 2022

28 February 2023

Quick facts

Lead sponsor	University of Oslo
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	459
Start date	7 March 2022
Primary completion	21 May 2022
Estimated completion	28 February 2023
Sites	1 location across Norway

Drugs / interventions tested

ICIT

Conditions studied

Medical Unexplained Physical Symptoms (MUPS) — all drugs for Medical Unexplained Physical Symptoms (MUPS) →
Subjective Health Complaint — all drugs for Subjective Health Complaint →

Sponsor

University of Oslo

Who can join

Adults 18 to 67, any sex, with Medical Unexplained Physical Symptoms (MUPS) or Subjective Health Complaint. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Many patients in general practice present symptoms that do not refer to specific pathology. We refer to these patients at Medical Unexplained Physical Symptoms (MUPS). Practice and research have well documented that these patients frustrate most General Practitioners (GPs). They also produce a lot of unnecessary investigations and are overrepresented on sick-listing. The conversational tool Individual Challenge Inventory Tool (ICIT) offers an aid for the GPS to the consultation and aims to increase the patients' coping abilities with their health challenges. The aim of the study is to investigate whether patients experience such increased coping following a session of consultations with their GP based on ICIT.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The effects of a structured communication tool in patients with medically unexplained physical symptoms: a cluster randomized trial.
Abrahamsen C, Reme SE, Wangen KR, Lindbæk M, et al · · 2023 · cited 17× · PMID 37855023 · DOI 10.1016/j.eclinm.2023.102262

Verify or expand the search:

Other University of Oslo trials

Trials by the same sponsor.

NCT07346911 — Digital Interventions for Relapse Prevention in Adolescence · NA · not yet recruiting
NCT07499219 — Preliminary Testing and Development of a Short Digital Intervention for Patients on Waiting Lists for Psychological Trea · NA · not yet recruiting
NCT07408687 — Mechanisms Of Change in Psychotherapy: The Effects of Cognitive Behavioral Therapy and Psychodynamic Therapy in Once - V · NA · not yet recruiting
NCT07287072 — Pain Reprocessing Therapy for Chronic Primary Pain · NA · not yet recruiting
NCT07428694 — From Bench to Bedside: A Machine Learning Tool for the Detection of Inspiratory Leak · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05128019 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oslo
Last refreshed: 17 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05128019.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing